Anticoagulant and anti-inflammatory effects after peritoneal lavage with antithrombin in experimental polymicrobial peritonitis

Journal of Thrombosis and Haemostasis

Volumn 4, Issue 11, 2006, Pages 2343-2351

  Van Veen, S Q ^a   Cheung, C W ^a   Meijers, J C M ^a   Van Gulik, T M ^a   Boermeester, Marja A ^a  

^a UNIVERSITY OF AMSTERDAM   (Netherlands)

Author keywords

Antithrombin; Inflammation; Peritonitis

Indexed keywords

CHEMOKINE; D DIMER; INTERLEUKIN 1BETA; INTERLEUKIN 6; MYELOPEROXIDASE; PLASMINOGEN ACTIVATOR INHIBITOR 1; RECOMBINANT ANTITHROMBIN III; SODIUM CHLORIDE; THROMBIN ANTITHROMBIN COMPLEX; TISSUE PLASMINOGEN ACTIVATOR; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIINFLAMMATORY ACTIVITY; ARTICLE; BLOOD CLOTTING; BLOOD CLOTTING TIME; CECUM; CONTROLLED STUDY; DRUG MEGADOSE; EXPERIMENTAL INFECTION; FIBRINOLYSIS; HISTOPATHOLOGY; INFLAMMATION; LEUKOCYTE COUNT; LIGATION; MALE; MOUSE; NONHUMAN; PERITONEUM LAVAGE; PERITONITIS; PRIORITY JOURNAL; PUNCTURE; SURVIVAL RATE;

ANIMALS; ANTITHROMBINS; CYTOKINES; DISEASE MODELS, ANIMAL; FIBRIN FIBRINOGEN DEGRADATION PRODUCTS; FIBRINOLYSIS; HUMANS; INFLAMMATION; MALE; MICE; PERITONEAL LAVAGE; PERITONITIS; PEROXIDASE; RECOMBINANT PROTEINS;

EID: 33750067955     PISSN: 15387933     EISSN: 15387836     Source Type: Journal    
DOI: 10.1111/j.1538-7836.2006.02167.x     Document Type: Article

References (44)

1. Levi M, ten Cate H. Disseminated intravascular coagulation. N Engl J Med 1999; 341: 586-92.
2. Minnema MC, Chang AC, Jansen PM, Lubbers YT, Pratt BM, Whittaker BG, Taylor FB, Hack CE, Friedman B. Recombinant human antithrombin III improves survival and attenuates inflammatory responses in baboons lethally challenged with Escherichia coli. Blood 2000; 95: 1117-23.
3. Yang S, Hauptman JG. The efficacy of heparin and antithrombin III in fluid-resuscitated cecal ligation and puncture. Shock 1994; 2: 433-7.
4. Dickneite G, Leithauser B. Influence of antithrombin III on coagulation and inflammation in porcine septic shock. Arterioscler Thromb Vasc Biol 1999; 19: 1566-72.
5. Warren BL, Eid A, Singer P, Pillay SS, Carl P, Novak I, Chalupa P, Atherstone A, Penzes I, Kubler A, Knaub S, Keinecke HO, Heinrichs H, Schindel F, Juers M, Bone RC, Opal SM. Caring for the critically ill patient. High-dose antithrombin III in severe sepsis: A randomized controlled trial. JAMA 2001; 286: 1869-78.
6. Freeman BD, Zehnbauer BA, Buchman TG. A meta-analysis of controlled trials of anticoagulant therapies in patients with sepsis. Shock 2003; 20: 5-9.
7. Bleeker WK, Agterberg J, Rigter G, Hack CE, Gool JV. Protective effect of antithrombin III in acute experimental pancreatitis in rats. Dig Dis Sci 1992; 37: 280-5.
8. Marshall JC, Maier RV, Jimenez M, Dellinger EP. Source control in the management of severe sepsis and septic shock: An evidence-based review. Crit Care Med 2004; 32: S513-26.
9. Soons H, Tans G, Hemker HC. The heparin-catalysed inhibition of human factor XIa by antithrombin III is dependent on the heparin type. Biochem J 1988; 256: 815-20.
10. Pieters J, Willems G, Hemker HC, Lindhout T. Inhibition of factor IXa and factor Xa by antithrombin III/heparin during factor X activation. J Biol Chem 1988; 263: 15313-8.
11. Jesty J, Lorenz A, Rodriguez J, Wun TC. Initiation of the tissue factor pathway of coagulation in the presence of heparin: Control by antithrombin III and tissue factor pathway inhibitor. Blood 1996; 87: 2301-7.
12. Esmon CT. Role of coagulation inhibitors in inflammation. Thromb Haemost 2001; 86: 51-6.
13. Levi M, ten Cate H, Van Der Poll T. Endothelium: Interface between coagulation and inflammation. Crit Care Med 2002; 30: S220-4.
14. Opal SM. Therapeutic rationale for antithrombin III in sepsis. Crit Care Med 2000; 28: S34-7.
15. ten Cate H, Schoenmakers SH, Franco R, Timmerman JJ, Groot AP, Spek CA, Reitsma PH. Microvascular coagulopathy and disseminated intravascular coagulation. Crit Care Med 2001; 29: S95-7.
16. Dixon B. The role of microvascular thrombosis in sepsis. Anaesth Intensive Care 2004; 32: 619-29.
17. Ahrenholz DH, Simmons RL. Fibrin in peritonitis. I. Beneficial and adverse effects of fibrin in experimental E. coli peritonitis. Surgery 1980; 88: 41-7.
18. Qiu G, Gribbin E, Harrison K, Sinha N, Yin K. Inhibition of gamma interferon decreases bacterial load in peritonitis by accelerating peritoneal fibrin deposition and tissue repair. Infect Immun 2003; 71: 2766-74.
19. Wickel DJ, Cheadle WG, Mercer-Jones MA, Garrison RN. Poor outcome from peritonitis is caused by disease acuity and organ failure, not recurrent peritoneal infection. Ann Surg 1997; 225: 744-53.
20. Farthmann EH, Schoffel U. Epidemiology and pathophysiology of intraabdominal infections (IAI). Infection 1998; 26: 329-34.
21. Schein M, Wittmann DH, Holzheimer R, Condon RE. Hypothesis: compartmentalization of cytokines in intraabdominal infection. Surgery 1996; 119: 694-700.
22. Edmunds T, Van Patten SM, Pollock J, Hanson E, Bernasconi R, Higgins E, Manavalan P, Ziomek C, Meade H, McPherson JM, Cole ES. Transgenically produced human antithrombin: Structural and functional comparison to human plasma-derived antithrombin. Blood 1998; 91: 4561-71.
23. Van Veen SQ, Van Vliet AK, Wulferink M, Brands R, Boermeester MA, van Gulik TM. Bovine intestinal alkaline phosphatase attenuates the inflammatory response in secondary peritonitis in mice. Infect Immun 2005; 73: 4309-14.
24. Weijer S, Schoenmakers SH, Florquin S, Levi M, Vlasuk GP, Rote WE, Reitsma PH, Spek CA, Van Der Poll T. Inhibition of the tissue factor/ factor VIIa pathway does not influence the inflammatory or antibacterial response to abdominal sepsis induced by Escherichia coli in mice. J Infect Dis 2004; 189: 2308-17.
25. Branger J, Leemans JC, Florquin S, Speelman P, Golenbock DT, Van Der Poll T. Lipopolysaccharide binding protein-deficient mice have a normal defense against pulmonary mycobacterial infection. Clin Immunol 2005; 116: 174-81.
26. van Westerloo DJ, Giebelen IA, Florquin S, Daalhuisen J, Bruno MJ, de Vos AF, Tracey KJ, Van Der Poll T. The cholinergic anti-inflammatory pathway regulates the host response during septic peritonitis. J Infect Dis 2005; 191: 2138-48.
27. Fourrier F, Chopin C, Goudemand J, Hendrycx S, Caron C, Rime A, Marey A, Lestavel P. Septic shock, multiple organ failure, and disseminated intravascular coagulation. Compared patterns of antithrombin III, protein C, and protein S deficiencies. Chest 1992; 101: 816-23.
28. Ilias W, List W, Decruyenaere J, Lignian H, Knaub S, Schindel F, Keinecke HO, Heinrichs H, Thijs LG. Antithrombin III in patients with severe sepsis: A pharmacokinetic study. Intensive Care Med 2000; 26: 704-15.
29. Schorr M, Siebeck M, Zugel N, Welcker K, Gippner-Steppert C, Czwienzek E, Groschler M, Jochum M. Antithrombin III and local serum application: adjuvant therapy in peritonitis. Eur J Clin Invest 2000; 30: 359-66.
30. Opal SM, Kessler CM, Roemisch J, Knaub S. Antithrombin, heparin, and heparan sulfate. Crit Care Med 2002; 30: S325-31.
31. Key NS, Ely EW. Coagulation inhibition for sepsis. Curr Opin Hematol 2002; 9: 416-21.
32. Idell S. Coagulation, fibrinolysis, and fibrin deposition in acute lung injury. Crit Care Med 2003; 31: S213-20.
33. Giebler R, Schmidt U, Koch S, Peters J, Scherer R. Combined antithrombin III and C1-esterase inhibitor treatment decreases intravascular fibrin deposition and attenuates cardiorespiratory impairment in rabbits exposed to Escherichia coli endotoxin. Crit Care Med 1999; 27: 597-604.
34. Mercer-Jones MA, Shrotri MS, Peyton JC, Remick DG, Cheadle WG. Neutrophil sequestration in liver and lung is differentially regulated by C-X-C chemokines during experimental peritonitis. Inflammation 1999; 23: 305-19.
35. Hoffmann JN, Vollmar B, Inthorn D, Schildberg FW, Menger MD. Antithrombin reduces leukocyte adhesion during chronic endotoxemia by modulation of the cyclooxygenase pathway. Am J Physiol Cell Physiol 2000; 279: C98-C107.
36. Minamiya Y, Saito S, Kalina U, Saito H, Terada K, Ogawa J. Antithrombin III diminishes production of oxygen radical in endotoxin-infused rat lung. Shock 2004; 21: 139-43.
37. Hoffmann JN, Muhlbayer D, Jochum M, Inthorn D. Effect of long-term and high-dose antithrombin supplementation on coagulation and fibrinolysis in patients with severe sepsis. Crit Care Med 2004; 32: 1851-9.
38. Souter PJ, Thomas S, Hubbard AR, Poole S, Romisch J, Gray E. Antithrombin inhibits lipopolysaccharide-induced tissue factor and interleukin-6 production by mononuclear cells, human umbilical vein endothelial cells, and whole blood. Crit Care Med 2001; 29: 134-9.
39. Otero-Anton E, Gonzalez-Quintela A, Lopez-Soto A, Lopez-Ben S, Llovo J, Perez LF. Cecal ligation and puncture as a model of sepsis in the rat: influence of the puncture size on mortality, bacteremia, endotoxemia and tumor necrosis factor alpha levels. Eur Surg Res 2001; 33: 77-9.
40. Peterson CB, Blackburn MN. Isolation and characterization of an antithrombin III variant with reduced carbohydrate content and enhanced heparin binding. J Biol Chem 1985; 260: 610-5.
41. Kahlke V, Dohm C, Mees T, Brotzmann K, Schreiber S, Schroder J. Early interleukin-10 treatment improves survival and enhances immune function only in males after hemorrhage and subsequent sepsis. Shock 2002; 18: 24-8.
42. Diodato MD, Knoferl MW, Schwacha MG, Bland KI, Chaudry IH. Gender differences in the inflammatory response and survival following haemorrhage and subsequent sepsis. Cytokine 2001; 14: 162-9.
43. Angele MK, Schwacha MG, Ayala A, Chaudry IH. Effect of gender and sex hormones on immune responses following shock. Shock 2000; 14: 81-90.
44. Oberholzer A, Souza SM, Tschoeke SK, Oberholzer C, Abouhamze A, Pribble JP, Moldawer LL. Plasma cytokine measurements augment prognostic scores as indicators of outcome in patients with severe sepsis. Shock 2005; 23: 488-93.